Christopher James Stevens Insider Profile
4 Followers
Christopher James Stevens, COO at Rocket Pharmaceuticals, holds 505.78K shares in Rocket Pharmaceuticals (Ticker: RCKT). Most recently, Christopher James Stevens Sold 36,658 shares of Rocket Pharmaceuticals on Aug 13, 2026 for an estimated value of $127.94K.
Christopher James Stevens has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Christopher James Stevens's holdings
Insider Roles
COO
Roles that Christopher James Stevens holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Christopher James Stevens
Christopher James Stevens's Trading History
List of latest transactions for each holding click on a transaction to see Christopher James Stevens's performance on stock
You May Also Like
Christopher James Stevens insider profile FAQ
What is the percentage of profitable transactions made by Christopher James Stevens?
The percentage of profitable transactions made by Christopher James Stevens is ―.
What is the average return per transaction made by Christopher James Stevens?
The average return per transaction made by Christopher James Stevens is ―.
What stocks does Christopher James Stevens hold?
Christopher James Stevens holds: RCKT stocks.
What was Christopher James Stevens’s latest transaction?
Christopher James Stevens latest transaction was an Informative Sell of $127.94K.
What was Christopher James Stevens's most profitable transaction?
Christopher James Stevens’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Christopher James Stevens's role in Rocket Pharmaceuticals?
Christopher James Stevens's role in Rocket Pharmaceuticals is COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.